Silarus Therapeutics

United States
San Diego, California, United States, 92037

Company profile

Silarus Therapeutics company profile

Silarus Therapeutics is developing therapeutics targeting erythroferrone for the treatment of iron deficiency and iron overload disorders. Erythroferrone is a recently-discovered hormone that regulates the iron supply for red blood cell production. Iron deficiency, also known as anemia, is a condition in which blood does not contain the normal amount of red blood cells or lacks the proper amount of hemoglobin. This, in turn, lowers the amount of oxygen-rich blood in circulation, causing shortness of breath, dizziness or headaches.

Business identity

Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0-$1M
Founded
2014-01-01, Year

Headquarters

Postal code
92037
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
1
Total equity funding
$10M
Last funding
Series A / $10M / 2014-09-22
Last equity funding
Series A / $10M
Investors
2
Lead investors
2
Founders
2
Articles
1

Founders and investors

Founders

Elizabeta NemethTomas Ganz

Lead investors

Avalon VenturesGlaxoSmithKline

Investors

Avalon VenturesGlaxoSmithKline